REG - Advanz Pharma Holdco - Rule 19.6(c) Announcement

LivanovaAnnouncement

07/06/2022 17:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220607:nRSG0451Oa&default-theme=true

RNS Number : 0451O  Advanz Pharma Holdco Limited  07 June 2022

THE FOLLOWING ANNOUNCEMENT IS BEING MADE PURSUANT TO THE REQUIREMENTS OF RULE
19.6(C) OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE"), WHICH, INTER
ALIA, REQUIRES A PARTY TO AN OFFER TO MAKE AN ANNOUNCEMENT AT THE END OF A
PERIOD OF 12 MONTHS FROM THE DATE ON WHICH THE OFFER PERIOD ENDED CONFIRMING
WHETHER IT HAS TAKEN, OR NOT TAKEN, THE COURSE OF ACTION SET OUT IN ITS STATED
INTENTIONS

 

FOR IMMEDIATE RELEASE

7 June 2022

Advanz Pharma Holdco Limited

(formerly Cidron Aida Bidco Limited)

("Advanz Holdco")

Rule 19.6(c) confirmation in respect of post-offer intention statements made
in relation to Advanz Pharma Corp. Limited ("Advanz")

 

 

Advanz Holdco announces that, further to the completion of its recommended
cash offer for the entire issued and to be issued share capital of Advanz,
which was implemented by way of a scheme of arrangement under Article 125 of
the Companies (Jersey) Law 1991 and which became effective on 1 June 2021, it
has duly confirmed in writing to The Panel on Takeovers and Mergers in
accordance with the requirements of Rule 19.6(c) of the Code that it has
complied with its post-offer intention statements made pursuant to Rules
2.7(c)(viii) and 24.2 of the Code (as detailed in its announcement of 27
January 2021 and the scheme document published on 25 February 2021).

 

 

 

 

Enquiries:

 

Advanz Pharma Holdco Limited

Katarina
Janerud
Tel: +46 8 440 50 50

 

Morgan Stanley & Co. International plc (Financial Adviser to Advanz
Holdco)

David Kitterick
 
Tel: +44 20 7425 8000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  OUPZDLFBLQLZBBV